WHAT YOU NEED TO KNOW In case you missed it, Morning Consult published an op-ed by Matthew Lane, executive director of the Coalition Against Patent Abuse, around rising prescription drug prices and the need for reforms that can encourage competition and innovation to drive access and affordability.  In his op-ed, Lane highlights a national survey by the Campaign for […]

Continue Reading

IN CASE YOU MISSED IT: This week, Morning Consult published an op-ed by Matthew Lane, executive director of the Coalition Against Patent Abuse, around rising prescription drug prices and the need for reforms that can encourage competition and innovation to drive access and affordability.  In his op-ed, Lane highlights a recent national survey by the Campaign for Sustainable Rx Pricing, […]

Continue Reading

WHAT YOU NEED TO KNOW This week, Axios reported that Humira, a medicine that is prescribed to millions of people around the world, “continues to generate more U.S. revenue than any other drug, due to AbbVie extending U.S. patents and consequently retaining higher U.S. prices.”   WHAT YOU NEED TO KNOW: While Humira is notably one of the […]

Continue Reading

IN CASE YOU MISSED IT: This week, Axios reported that Humira, a medicine that treats a number of chronic conditions and is widely prescribed and used by millions of people around the world, reached $19.9 billion in global sales in 2018, marking an 8.2 percent increase from 2017.  While Humira is notably one of the most profitable […]

Continue Reading

WHAT YOU NEED TO KNOW Recently, CAPA hosted an online panel on the importance of balancing the needs of innovation, access, and affordability when it comes to drug policy.  The panel entitled, “Drug Pricing Debate: Why Drug Innovation, Access & Affordability Matter More Than Ever During COVID-19” welcomed discussion with leading experts in the field, […]

Continue Reading